Neurocrine Biosciences Inc (NBIX: NASDAQ)
$53.25 -1.12 | -2.06%
12/01/15 - 04:00 PM ET
1.10M / 1.14MVol / Avg. Vol:
54.57 / 54.37Open / Prev. Close:
52.68 - 54.9Today's Range:
18.59 - 58.4652 Wk Range:
Portfolios with NBIX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks With Big Insider Buy...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Drug Stock Winners of 2010
- UserKareem Portfolio
- UserSUPRATRADE Top 10 Micro Cap...
- UserBVF Inc.
- UserRAPTOR SPRTD-1110080822
Latest NBIX Headlines from TheStreet
- Water-Logged And Getting Wetter Stock Of The Day: Neurocrine Biosciences (NBIX) 07.20.15 | 11:07 am
- Neurocrine Biosciences (NBIX) Highlighted As Today's Perilous Reversal Stock 05.14.15 | 09:05 am
- First Week of NBIX June 19th Options Trading 04.23.15 | 11:04 am
- Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference 03.30.15 | 08:03 pm
- Short Interest In Neurocrine Biosciences Drops 20.6% 03.11.15 | 03:03 pm
- Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options 12.24.14 | 12:12 pm
- 2 Big-Volume Biotech Stocks to Trade for Breakouts 09.25.14 | 09:09 am
- The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks 08.26.14 | 02:08 pm
- NBIX Crosses Above Key Moving Average Level 08.06.14 | 11:08 am
- Commit To Purchase Neurocrine Biosciences At $12, Earn 27.6% Annualized Using Options 07.08.14 | 11:07 am
Press Releases for NBIX
- Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2015 Results - PR Newswire 07.22.15 | 01:07 pm
- Neurocrine Biosciences Provides Update On NBI-77860 Program For Congenital Adrenal Hyperplasia - PR Newswire 06.08.15 | 04:06 pm
- Neurocrine Biosciences, Inc. Announces Appointment Of Eric Benevich As Chief Commercial Officer - PR Newswire 06.02.15 | 08:06 am
- Neurocrine Biosciences To Present At The Jefferies 2015 Healthcare Conference - PR Newswire 05.27.15 | 03:05 pm
- Neurocrine Biosciences To Host Analyst And Investor Day In New York City On May 21, 2015 - PR Newswire 05.12.15 | 04:05 pm
- Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference - PR Newswire 05.08.15 | 01:05 pm
- Neurocrine Biosciences, Inc. Announces Appointment Of Dr. Bill Aurora As Vice President, Medical Affairs - PR Newswire 05.04.15 | 04:05 pm
- Neurocrine Biosciences To Present At The Deutsche Bank 40th Annual Health Care Conference - PR Newswire 04.30.15 | 01:04 pm
- Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2015 Results - PR Newswire 04.23.15 | 01:04 pm
- Neurocrine Biosciences And Mitsubishi Tanabe Pharma Announce Agreement To Develop And Commercialize VMAT2 Inhibitor NBI-98854 For Movement Disorders In Japan And Other Select Asian Markets - PR Newswire 03.31.15 | 10:03 pm
Partner Headlines for NBIX
- Neurocrine treatment for TD could see strong adoption, says Jefferies - The Fly 10.19.15 | 07:10 am
- Neurocrine price target raised to $71 from $67 at Leerink - The Fly 10.12.15 | 06:10 am
- Neurocrine price target raised to $96 from $86 at Piper Jaffray - The Fly 10.08.15 | 10:10 am
- Neurocrine Biosciences Rises as Drug Fights Movement Disorder - Bloomberg 10.08.15 | 10:10 am
- Neurocrine data for NBI-98854 'game-changing,' says JPMorgan - The Fly 10.08.15 | 10:10 am
- Leerink reiterates Outperform on Neurocrine after call with neurologists - The Fly 09.22.15 | 06:09 am
- Elagolix could be worth $12 to Neurocrine shares, says Deutsche Bank - The Fly 09.16.15 | 10:09 am
- Neurocrine price target raised to $66 from $59 at JPMorgan - The Fly 09.10.15 | 07:09 am
- Neurocrine coverage assumed with a Buy at Jefferies - The Fly 08.18.15 | 07:08 am
- Neurocrine resumed with an Outperform at Leerink - The Fly 07.21.15 | 08:07 am